New combo therapy shows promise for Tough-to-Treat endometrial cancer

NCT ID NCT04106414

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 26 times

Summary

This study tests whether adding an experimental drug (BMS-986205) to the immunotherapy nivolumab can shrink tumors or stop them from growing in people with endometrial cancer that has come back or not gone away. About 24 adults with certain types of endometrial cancer will receive either nivolumab alone or both drugs. The goal is to see if the combination works better, though it may also cause more side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Cancer Center @ Suffolk

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.